PL2603206T3 - Kompozycje farmaceutyczne antagonistów metabotropowego receptora glutaminianu 5 (mGLU5) - Google Patents

Kompozycje farmaceutyczne antagonistów metabotropowego receptora glutaminianu 5 (mGLU5)

Info

Publication number
PL2603206T3
PL2603206T3 PL11746215T PL11746215T PL2603206T3 PL 2603206 T3 PL2603206 T3 PL 2603206T3 PL 11746215 T PL11746215 T PL 11746215T PL 11746215 T PL11746215 T PL 11746215T PL 2603206 T3 PL2603206 T3 PL 2603206T3
Authority
PL
Poland
Prior art keywords
mglu5
antagonists
receptor
pharmaceutical compositions
metabotropic glutamate
Prior art date
Application number
PL11746215T
Other languages
English (en)
Inventor
Ashish Chatterji
Jingjun Huang
Stephanie Koennings
Kai Lindenstruth
Harpreet K Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2603206T3 publication Critical patent/PL2603206T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
PL11746215T 2010-08-11 2011-08-08 Kompozycje farmaceutyczne antagonistów metabotropowego receptora glutaminianu 5 (mGLU5) PL2603206T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37269310P 2010-08-11 2010-08-11
EP11746215.0A EP2603206B1 (en) 2010-08-11 2011-08-08 Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
PCT/EP2011/063602 WO2012019989A2 (en) 2010-08-11 2011-08-08 Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Publications (1)

Publication Number Publication Date
PL2603206T3 true PL2603206T3 (pl) 2017-10-31

Family

ID=44509316

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11746215T PL2603206T3 (pl) 2010-08-11 2011-08-08 Kompozycje farmaceutyczne antagonistów metabotropowego receptora glutaminianu 5 (mGLU5)

Country Status (24)

Country Link
US (5) US20120039999A1 (pl)
EP (2) EP2808022A1 (pl)
JP (2) JP2013533299A (pl)
KR (2) KR101800518B1 (pl)
CN (2) CN103068374B (pl)
AR (1) AR082602A1 (pl)
AU (1) AU2011288555B2 (pl)
BR (1) BR112013003158B1 (pl)
CA (1) CA2804749C (pl)
DK (1) DK2603206T3 (pl)
ES (1) ES2608727T3 (pl)
HK (1) HK1181653A1 (pl)
HU (1) HUE031220T2 (pl)
IL (1) IL224032B (pl)
MX (1) MX338634B (pl)
MY (1) MY164306A (pl)
NZ (1) NZ605424A (pl)
PL (1) PL2603206T3 (pl)
RU (1) RU2602955C2 (pl)
SG (1) SG187550A1 (pl)
SI (1) SI2603206T1 (pl)
TW (1) TW201211024A (pl)
WO (1) WO2012019989A2 (pl)
ZA (1) ZA201300500B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031395B1 (ru) * 2013-06-12 2018-12-28 Новартис Аг Состав с модифицированной кинетикой высвобождения
JO3543B1 (ar) * 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE
WO2021245281A1 (en) 2020-06-05 2021-12-09 Noema Pharma Ag Methods of treatment of tuberous sclerosis complex

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
IL85538A (en) * 1987-02-27 1991-09-16 Lilly Co Eli Sustained release matrix tablet formulations containing hydrophilic and enteric polymers
FR2677886B1 (fr) 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
US5656291A (en) 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
CN1094948A (zh) * 1993-05-13 1994-11-16 格拉克索加拿大有限公司 控制释放装置
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6475493B1 (en) * 1999-09-02 2002-11-05 Norstrum Pharmaceuticals, Inc. Controlled release pellet formulation
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP4690395B2 (ja) 2004-06-01 2011-06-01 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕ５レセプターアンタゴニストとしてのピリジン−４−エチニル−イミダゾール及びピラゾール
EP1756086B1 (en) * 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
AU2007336369B2 (en) * 2006-12-21 2013-01-17 F. Hoffmann-La Roche Ag Polymorphs of a mGluR5 receptor antagonist
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Also Published As

Publication number Publication date
AU2011288555A1 (en) 2013-01-24
US20220241260A9 (en) 2022-08-04
RU2013108057A (ru) 2014-09-20
CN103068374A (zh) 2013-04-24
HUE031220T2 (hu) 2017-07-28
KR20130028991A (ko) 2013-03-20
KR20150034254A (ko) 2015-04-02
CN105012301A (zh) 2015-11-04
US20170202819A1 (en) 2017-07-20
ES2608727T3 (es) 2017-04-12
ZA201300500B (en) 2013-09-25
CN105012301B (zh) 2018-09-11
IL224032B (en) 2018-03-29
CN103068374B (zh) 2015-08-26
US20120039999A1 (en) 2012-02-16
BR112013003158B1 (pt) 2021-07-06
DK2603206T3 (da) 2017-01-02
JP6113203B2 (ja) 2017-04-12
MY164306A (en) 2017-12-15
WO2012019989A3 (en) 2012-08-02
TW201211024A (en) 2012-03-16
KR101800518B1 (ko) 2017-11-22
US20210052567A1 (en) 2021-02-25
JP2013533299A (ja) 2013-08-22
JP2015107986A (ja) 2015-06-11
NZ605424A (en) 2015-01-30
RU2602955C2 (ru) 2016-11-20
CA2804749C (en) 2018-05-22
HK1181653A1 (en) 2013-11-15
CA2804749A1 (en) 2012-02-16
EP2808022A1 (en) 2014-12-03
EP2603206B1 (en) 2016-11-02
AR082602A1 (es) 2012-12-19
SI2603206T1 (sl) 2017-01-31
SG187550A1 (en) 2013-03-28
US20150140087A1 (en) 2015-05-21
BR112013003158A2 (pt) 2016-06-28
MX338634B (es) 2016-04-26
MX2013000860A (es) 2013-02-27
EP2603206A2 (en) 2013-06-19
AU2011288555B2 (en) 2016-02-18
WO2012019989A2 (en) 2012-02-16
US20190216789A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
HK1181654A1 (zh) 代謝型谷氨酸受體 拮抗劑的藥物組合物
HUS2300037I1 (hu) Piperidinon karboxamid azaindan CGRP receptor antagonisták
EP2461809A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
ZA201207259B (en) 4-aminopyrimidine derivatives and their as as adenosine 121 receptor antagonists
EP2927224B8 (en) Receptor antagonists
PL2453895T3 (pl) (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne
PL2593095T3 (pl) (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
EP2721011A4 (en) EP2 RECEPTOR ANTAGONISTS OF PROSTAGLANDINS, DERIVATIVES, COMPOSITIONS AND USES THEREOF
EP2619204A4 (en) TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS
PT2709631T (pt) Antagonistas de receptor de cb1
SG11201402269RA (en) NOVEL 2H-INDAZOLES AS EP<sb>2</sb> RECEPTOR ANTAGONISTS
HK1181653A1 (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists 5(mglu5)
HK1178902A1 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin b1 receptor b1
ZA201405959B (en) Novel neurokinin 1 receptor antagonist compounds
EP2627329A4 (en) TRPA1 RECEPTOR ANTAGONIST
EP2617717A4 (en) ANTAGONIST OF P2X4 RECEIVER
EP2791135A4 (en) COMPOUNDS AND COMPOSITIONS COVERED BY NICOTINE RECEPTOR
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.
WO2012094437A3 (en) Nicotinic receptor non-competitive antagonists
HU1000624D0 (en) Novel salts skitable for the preparation of pharmaceutical compositions
WO2013067105A3 (en) Nicotinic receptor non-competitive modulators